FDA reviews cardiovascular risks associated with Stalevo - ONA
Links shared publicly online about this topic.
- 927total visits
FDA reviews cardiovascular risks associated with Stalevo - ONA
View full resource at oncologynurseadvisor.com
Tags: Heart, Parkinson's Disease Medication, Healthcare, Clinical Trial, FDA, Sinemet, Novartis, Event
Most Recently Shared on August 23, 2010 at 2:08 pm By:
FDA reviews cardiovascular risks associated with Stalevo http://goo.gl/fb/dQsmq
Medical News: FDA Panel to Review Safety of Echo Contrast Agents - in Cardiovascular, Acute Coronary Syndrome from MedPage Today
medpagetoday.com — “WASHINGTON -- Adverse events associated with microbubble contrast agents used in echocardiography appear to be rare, but the agents might carry some risk of serious harm and fatalities, particularly i” View full resource at medpagetoday.com
Most Recently Shared on April 30, 2011 at 2:41 pm By:
Thomas Loarie, Jr Health Advocate
@medpagetoday FDA Panel to Review Safety of Echo Contrast Agents http://bit.ly/ihpM6M #medical #Health
Medical News: FDA Panel to Review Safety of Echo Contrast Agents - in Cardiovascular, Acute Coronary Syndrome from MedPage Today
medpagetoday.com — “WASHINGTON -- Adverse events associated with microbubble contrast agents used in echocardiography appear to be rare, but the agents might carry some risk of serious harm and fatalities, particularly i” View full resource at medpagetoday.com
Most Recently Shared on April 30, 2011 at 2:40 pm By:
Patricia Grace Eldercare Expert
FDA Panel to Review Safety of Echo Contrast Agents: WASHINGTON (MedPage Today) -- Adverse events associated with... http://bit.ly/lf68mY
Medical News: FDA Panel to Review Safety of Echo Contrast Agents - in Cardiovascular, Acute Coronary Syndrome from MedPage Today
medpagetoday.com — “WASHINGTON -- Adverse events associated with microbubble contrast agents used in echocardiography appear to be rare, but the agents might carry some risk of serious harm and fatalities, particularly i” View full resource at medpagetoday.com
Most Recently Shared on April 30, 2011 at 2:37 pm By:
FDA Panel to Review Safety of Echo Contrast Agents: WASHINGTON (MedPage Today) -- Adverse events associated with microb.. http://dld.bz/Yt4U
FDA reviews cardiovascular risks associated with Stalevo - MPR
empr.com — “The FDA has notified healthcare professionals that clinical trial data suggesting that Stalevo (carbidopa, levodopa, entacapone, from Novartis) increases the risk for cardiovascular events compared to carbidopa/levodopa (Sinemet, from Bristol-Myers Squibb) is being evaluated.” View full resource at empr.com
Most Recently Shared on August 23, 2010 at 2:12 pm By:
MPR News: FDA reviews cardiovascular risks associated with Stalevo: The FDA has notified healthcare professionals ... http://bit.ly/bTzIjD
FDA Alert: Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk
drugs.com — “FDA Alert: Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk” View full resource at drugs.com
Most Recently Shared on August 22, 2010 at 11:37 pm By:
FDA Alert - Ongoing Safety Review: Stalevo (carbidopa/levodopa and entacapone) - http://bit.ly/90MUk2
Parkinson's Drug Under FDA Review: Stalevo Suspected of Upping Cardiovascular Risk - QualityPoint Technologies
qualitypointtech.net — “The cardiovascular status of patients taking a combination of carbidopa/levodopa and entacapone should be checked, but they should not discontinue the drug unless advised to do so by their physician. Medscape Medical News” View full resource at qualitypointtech.net
Most Recently Shared on August 21, 2010 at 2:27 pm By:
Parkinson's Drug Under FDA Review: Stalevo Suspected of Upping Cardiovascular Risk: The cardiovascular status of ... http://bit.ly/aVLMM3
FDA reviews cardiovascular mortality risk associated with Benicar - MPR
empr.com — “The FDA is evaluating data from two clinical trials in which patients with type 2 diabetes taking Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) had a higher rate of death from a cardiovascular cause compared to patients taking a placebo.” View full resource at empr.com
Most Recently Shared on June 12, 2010 at 12:36 am By:
MPR News: FDA reviews cardiovascular mortality risk associated with Benicar: The FDA is evaluating data from two c... http://bit.ly/aP5oN6
Avandia (rosiglitazone): Ongoing Review of Cardiovascular Safety
fda.gov — “FDA is reviewing data from a large, long-term clinical study on possible risks for cardiovascular outcomes associated with use of rosiglitazone.” View full resource at fda.gov
Most Recently Shared on February 22, 2010 at 9:32 pm By:
eyeonfda Pharma and Health Lawyer
FDA issues MedWatch - Avandia (rosiglitazone): Ongoing Review of Cardiovascular Safety - http://ow.ly/1a4EB
Advertisement
